FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005109148> ?p ?o ?g. }

• W2005109148 endingPage "7" @default.
• W2005109148 startingPage "5" @default.
• W2005109148 abstract "This article inroduces a series of reviews covering Mucosal Immunity in Volume 260 of Immunological Reviews. Most antigens encountered by the immune system enter the body through the mucosal surfaces of the respiratory, gastrointestinal (GI), and urogenital tract, and the vast majority of pathogens use these tissues as portals of entry. An additional feature of these tissues is their constitutive and ever evolving relationship with highly diverse and site-specific microbial communities referred to as the microbiota 1. Barrier sites are therefore charged with the formidable task of mediating the host relationship with its microbiota, protecting the host from environmental and pathogenic challenges while preserving vital physiological functions. At these sites, failure to control responses can lead to severe inflammatory disorders including asthma, inflammatory bowel disease, psoriasis, or food allergies. The incidence of these chronic inflammatory diseases, as with most pathologies targeting barrier tissues, has risen significantly for the past several decades 2. Understanding how immunity is controlled at barrier tissues as well as the key stressors of these environments is not only of major public health interest, but is also the object of intensive investigation. This issue of Immunological Reviews presents articles from investigators involved in the exploration of the mechanisms by which mucosal barrier sites induce and control innate and adaptive immune responses. The body's epithelial surfaces act as a scaffold to sustain diverse communities of commensals that include bacteria, archaea, fungi, protozoa, and viruses 3-7. With an estimated composition of 100 trillion cells, commensals outnumber host cells by at least a factor of 10 and encode at least 100 times more unique genes than their host's genome 8. These microbes represent a formidable challenge for the immune system, and as such, a large fraction of the mucosal immune network is aimed at limiting reactivity or exposure to the microbiota. To maintain a homeostatic relationship with the microbiota and limit antigenic and pathogen exposure, protection is primarily mediated by an epithelial layer that forms a physical barrier and is supported by both adaptive and innate arms of the immune system. Over the past few years, it has become clear that epithelial cells, via their capacity to produce mucus, antimicrobial peptides, metabolites, or cytokines, are a central determinant of immunity in tissue microenvironments 9. As discussed in this volume by Gunnar Hansson and colleagues 10, the mucus layer, built around the gel-forming mucins, covers all mucosal surfaces therefore limiting pathogenic invasion and contact with epithelial cells. However, this primary shield is not absolute, and a certain degree of controlled reactivity to the microbiota contributes to reinforce barrier immunity and function. Appropriate responses to the microbiota are established soon after birth upon exposure of the immune system to commensals during the passage through the birth canal. Expanding on this concept, Fulde and Hornef 11 discuss how early adaptation of innate cells to microbial stimulation set the tone of subsequent responses to the microbiota. As further discussed by Fung et al. 12, containment of the microbiota thorough life represents a formidable task for the mucosal immune system that requires the continuous and combined action of epithelial cells, adaptive immunity, and innate population of lymphocytes. One of these mechanisms is associated with immunoglobulin A (IgA) responses. About three quarters of total antibody production is composed of IgA, in the order of 3–5 g produced per day in humans, with the vast majority secreted across barrier surfaces. The reviews of Slack et al. 13, Kato et al. 14, and Gutzeit et al. 15 discuss the various and fundamental roles of IgA in regulating mucosal immunity. Notably, these authors discuss how IgA shape the microbiota, mediate pathogen clearance, neutralize toxins, and prevent adhesion of commensal bacteria to the epithelial surfaces by generating steric hindrance. The complex and dynamic control of mucosal immunity requires an arsenal of defined tissue-specific factors and highly specialized innate and adaptive immune cell types, specifically conditioned by the mucosal environment to induce tissue tailored immunity (Fig. 1). These networks converge to prevent overt reactivity to commensal and environmental antigens and to favor the induction and maintenance of tolerogenic responses. Antigen-presenting cells (APCs) play an important role in this tissue immune specialization, and each mucosal site is seeded by defined APCs. The gut notably is home to a highly specialized and complex network of APCs. These gut APCs, in addition to monocytes recruited from the blood during inflammation, form the mononuclear phagocyte system of the GI tract. Reviews from Agace and colleagues 16, Mowat and colleagues 17, and Maria Rescigno 18 highlight the complexity and versatility of the intestinal APC network and particularly how the function and development of these cells is conditioned by local cues derived from the diet or epithelial cells. The results of this local tuning are the induction of tolerogenic responses via the induction of various populations of regulatory T cells. Together, these reviews also discuss the contextual role of gut APCs in both maintaining tolerance in steady state and promoting effector responses during infection or chronic inflammation. Indeed, tolerance to the microbiota or environmental antigen is not the only fate of immune responses at mucosal sites. Reactivity of barrier tissue is a vital requirement for the host, as the majority of pathogenic microbes target or are acquired through mucosal surfaces of the GI, respiratory, and genital tracts. To this end, and as discussed by McAleer and Kolls 19 and Cho and Kelsall 20, mucosal tissues are constitutively enriched in cytokines such as interleukin-17 (IL-17), IL-22, or type I interferon (IFN). Despite the specialization of each tissue and microenvironment, the expression of these cytokines is relatively conserved between mucosal sites such as the lung and GI tract. Via their capacity to act both on epithelial cells and to control inflammatory cells, IL-22 and cytokines of the IL-17 family contribute to both mucosal homeostasis and immunity 21, 22. Stephen McSorley 23 also discusses how immunity to a pathogen such as Salmonella develops and is controlled in the GI tract, while Grencis et al. 24 highlight how the mucosal immune system has evolved mechanisms promoting type 2 immunity to allow coexistence with nematodes. As previously discussed, barrier sites are primary sites of inflammatory disorders. When operating optimally, the mucosal immune system network interweaves the innate and adaptive arms of immunity in a dialogue that selects, calibrates, and terminates responses in the most appropriate manner. However, as discussed by Elson 25, Jabri 26, Umetsu 27, and Strober 28 and their colleagues, breakdown in the capacity of the host to maintain regulatory responses to the multitude of antigens encountered by mucosal tissues represents the underlying cause of severe inflammatory disorders such as inflammatory bowel disease, allergy, and asthma that increasingly affect barrier sites in westernized countries. Collectively, this group of reviews highlight the rapidly growing knowledge of the pathways and cell types that regulate immune cell homeostasis at mucosal surfaces and inflammation and discuss some of the future challenges to be addressed in understanding barrier immunity in the context of infection, inflammation, and tissue repair. This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health." @default.
• W2005109148 created "2016-06-24" @default.
• W2005109148 creator A5065888325 @default.
• W2005109148 date "2014-06-19" @default.
• W2005109148 modified "2023-09-27" @default.
• W2005109148 title "Tailored immunity at mucosae" @default.
• W2005109148 cites W1965727970 @default.
• W2005109148 cites W1976611079 @default.
• W2005109148 cites W1979891329 @default.
• W2005109148 cites W1981389563 @default.
• W2005109148 cites W1982229304 @default.
• W2005109148 cites W1989972789 @default.
• W2005109148 cites W1999615949 @default.
• W2005109148 cites W2004499885 @default.
• W2005109148 cites W2013274771 @default.
• W2005109148 cites W2014293700 @default.
• W2005109148 cites W2022737640 @default.
• W2005109148 cites W2032240345 @default.
• W2005109148 cites W2034372373 @default.
• W2005109148 cites W2034819118 @default.
• W2005109148 cites W2036743290 @default.
• W2005109148 cites W2050706371 @default.
• W2005109148 cites W2052437948 @default.
• W2005109148 cites W2054666047 @default.
• W2005109148 cites W2064156437 @default.
• W2005109148 cites W2090925778 @default.
• W2005109148 cites W2098019567 @default.
• W2005109148 cites W2102526590 @default.
• W2005109148 cites W2133929474 @default.
• W2005109148 cites W2146890677 @default.
• W2005109148 cites W2152011851 @default.
• W2005109148 cites W2159633664 @default.
• W2005109148 cites W2161251845 @default.
• W2005109148 cites W2164510587 @default.
• W2005109148 doi "https://doi.org/10.1111/imr.12197" @default.
• W2005109148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4976456" @default.
• W2005109148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24942677" @default.
• W2005109148 hasPublicationYear "2014" @default.
• W2005109148 type Work @default.
• W2005109148 sameAs 2005109148 @default.
• W2005109148 citedByCount "3" @default.
• W2005109148 countsByYear W20051091482015 @default.
• W2005109148 countsByYear W20051091482016 @default.
• W2005109148 countsByYear W20051091482017 @default.
• W2005109148 crossrefType "journal-article" @default.
• W2005109148 hasAuthorship W2005109148A5065888325 @default.
• W2005109148 hasBestOaLocation W20051091481 @default.
• W2005109148 hasConcept C203014093 @default.
• W2005109148 hasConcept C2779341262 @default.
• W2005109148 hasConcept C86803240 @default.
• W2005109148 hasConcept C8891405 @default.
• W2005109148 hasConceptScore W2005109148C203014093 @default.
• W2005109148 hasConceptScore W2005109148C2779341262 @default.
• W2005109148 hasConceptScore W2005109148C86803240 @default.
• W2005109148 hasConceptScore W2005109148C8891405 @default.
• W2005109148 hasFunder F4320332161 @default.
• W2005109148 hasIssue "1" @default.
• W2005109148 hasLocation W20051091481 @default.
• W2005109148 hasLocation W20051091482 @default.
• W2005109148 hasLocation W20051091483 @default.
• W2005109148 hasLocation W20051091484 @default.
• W2005109148 hasOpenAccess W2005109148 @default.
• W2005109148 hasPrimaryLocation W20051091481 @default.
• W2005109148 hasRelatedWork W1963906481 @default.
• W2005109148 hasRelatedWork W2055735866 @default.
• W2005109148 hasRelatedWork W2093576198 @default.
• W2005109148 hasRelatedWork W2106309510 @default.
• W2005109148 hasRelatedWork W2124311711 @default.
• W2005109148 hasRelatedWork W2149972703 @default.
• W2005109148 hasRelatedWork W2178599865 @default.
• W2005109148 hasRelatedWork W2283522479 @default.
• W2005109148 hasRelatedWork W2948839444 @default.
• W2005109148 hasRelatedWork W4308039002 @default.
• W2005109148 hasVolume "260" @default.
• W2005109148 isParatext "false" @default.
• W2005109148 isRetracted "false" @default.
• W2005109148 magId "2005109148" @default.
• W2005109148 workType "article" @default.